The Preuss Foundation Seminar on vaccine therapy for malignant primary brain tumors. February 15-17, 1998, La Jolla, Calif.
Publication
, Journal Article
Sampson, JH
Published in: Neuro Oncol
January 1999
Duke Scholars
Published In
Neuro Oncol
DOI
ISSN
1522-8517
Publication Date
January 1999
Volume
1
Issue
1
Start / End Page
33 / 42
Location
England
Related Subject Headings
- Tumor Cells, Cultured
- Randomized Controlled Trials as Topic
- Prospective Studies
- Oncology & Carcinogenesis
- Nervous System Autoimmune Disease, Experimental
- Neoplastic Stem Cells
- Mice
- Melanoma, Experimental
- Immunotherapy, Active
- Immunocompromised Host
Citation
APA
Chicago
ICMJE
MLA
NLM
Sampson, J. H. (1999). The Preuss Foundation Seminar on vaccine therapy for malignant primary brain tumors. February 15-17, 1998, La Jolla, Calif. Neuro Oncol, 1(1), 33–42. https://doi.org/10.1093/neuonc/1.1.33
Sampson, J. H. “The Preuss Foundation Seminar on vaccine therapy for malignant primary brain tumors. February 15-17, 1998, La Jolla, Calif.” Neuro Oncol 1, no. 1 (January 1999): 33–42. https://doi.org/10.1093/neuonc/1.1.33.
Sampson JH. The Preuss Foundation Seminar on vaccine therapy for malignant primary brain tumors. February 15-17, 1998, La Jolla, Calif. Neuro Oncol. 1999 Jan;1(1):33–42.
Sampson, J. H. “The Preuss Foundation Seminar on vaccine therapy for malignant primary brain tumors. February 15-17, 1998, La Jolla, Calif.” Neuro Oncol, vol. 1, no. 1, Jan. 1999, pp. 33–42. Pubmed, doi:10.1093/neuonc/1.1.33.
Sampson JH. The Preuss Foundation Seminar on vaccine therapy for malignant primary brain tumors. February 15-17, 1998, La Jolla, Calif. Neuro Oncol. 1999 Jan;1(1):33–42.
Published In
Neuro Oncol
DOI
ISSN
1522-8517
Publication Date
January 1999
Volume
1
Issue
1
Start / End Page
33 / 42
Location
England
Related Subject Headings
- Tumor Cells, Cultured
- Randomized Controlled Trials as Topic
- Prospective Studies
- Oncology & Carcinogenesis
- Nervous System Autoimmune Disease, Experimental
- Neoplastic Stem Cells
- Mice
- Melanoma, Experimental
- Immunotherapy, Active
- Immunocompromised Host